Injectable Pricing & Rebate Tracker: Botox, Dysport, Jeuveau, Daxxify, Xeomin

Neurotoxin cost is typically quoted in two ways: per-unit (the smallest billable dose) and per-vial (the whole package). A 50-unit Botox vial costs roughly $400–$450 wholesale, depending on your volume tier and rebate status—that's $8–$9 per unit. Dysport (abobotulinumtoxinA) is approximately 1:3 potency to Botox, so a 150-unit Dysport vial at $300–$350 works out to $2–$2.33 per unit, but you're billing 3× the units to the patient. Jeuveau (prabotulinumtoxinA) typically prices at $6–$7 per unit. Daxxify (daxibotulinumtoxinA), the longest-acting option, commands a premium: $10–$12 per unit. Xeomin (incobotulinumtoxinA) sits at $7–$8 per unit. These are wholesale acquisition costs (WAC) before rebates; your actual landed cost depends entirely on your loyalty-program tier and cumulative annual volume with each manufacturer.

Allē is AbbVie's unified loyalty platform for Botox, Juvéderm fillers, and other Allergan Aesthetics products. Rebates are volume-tiered and cumulative across the entire Allergan portfolio, not just neurotoxins. A practice buying $50k annually in Botox alone may qualify for a 10–15% rebate; add $30k in Juvéderm and you unlock 18–22%. The rebate is typically paid quarterly as a credit against future purchases or as a check. Critically, Allē tracks your loyalty points in real time via their portal—you can see exactly how close you are to the next tier. Many practices miss rebate acceleration opportunities by not timing large purchases (e.g., stocking before a seasonal surge) to cross a threshold. AbbVie also runs promotional rebates (e.g., 'buy 10 vials of Botox, get $X back') that stack on top of tiered rebates. Track these in your purchasing calendar; they shift every quarter.

Galderma's Aspire program operates similarly to Allē but is Galderma-only (Dysport, Restylane fillers, Sculptra). Rebates are also volume-tiered and paid quarterly. Dysport rebates typically range 12–20% depending on annual spend. Galderma has been aggressive in market share capture—H1 2026 results showed record sales and raised full-year guidance, signaling continued investment in rebate incentives. One key difference: Galderma's rebate structure sometimes includes product-mix incentives (e.g., higher rebate if you buy a certain ratio of Dysport to fillers). This can be advantageous if your patient mix naturally skews toward combination treatments. Aspire also offers early-payment discounts (2–3% off if you pay net-15 instead of net-30), which compound with rebates. A practice paying early and hitting volume tiers can effectively reduce Dysport cost to $1.50–$1.80 per unit.

Evolus Rewards is Evolus's smaller but growing loyalty program for Jeuveau (prabotulinumtoxinA). Jeuveau is priced aggressively—typically $6–$7 per unit, undercutting Botox—to capture market share from practices seeking lower COGS. Evolus Rewards rebates are less generous than Allē or Aspire (typically 8–12% at mid-tier volumes) because Evolus's overall volume is lower. However, Jeuveau has gained traction among practices targeting price-sensitive patients or those seeking a 'clean' alternative narrative (no animal-derived ingredients). The real value of Evolus Rewards is predictability: smaller rebate swings, simpler tier structure, and less frequent promotional chaos. If your practice has a stable patient base and wants to lock in low per-unit costs without chasing quarterly promotions, Jeuveau + Evolus Rewards can be the right choice, even if the rebate percentage is lower.

Daxxify (daxibotulinumtoxinA), FDA-approved in 2023, is the longest-acting neurotoxin (results last up to 6 months vs. 3–4 for others). Wholesale cost is $10–$12 per unit, but patient pricing commands a 20–30% premium over Botox because of the extended duration. A practice charging $15–$18 per unit for Daxxify vs. $12–$14 for Botox can capture significant margin uplift on the same cost base. Daxxify is not yet on a major loyalty program (it's still building volume), so rebates are minimal. However, the high per-unit patient price and lower rebate dependency make Daxxify attractive for practices with strong patient education and premium positioning. Track Daxxify adoption carefully: as volume grows, expect AbbVie to fold it into Allē with tiered rebates, which will compress margins but increase volume incentives.

Set up a simple spreadsheet tracking monthly purchases by product, vial count, and cost. Calculate your blended per-unit cost (total COGS ÷ total units purchased) monthly and quarterly. Compare it to your average patient charge per unit; the gap is your gross margin before overhead. Log into Allē, Aspire, and Evolus Rewards portals monthly to monitor rebate accrual and tier progress. Many practices discover they're 1–2 vials away from a rebate threshold and can time a purchase to cross it. Negotiate your WAC directly with your group purchasing organization (GPO) or manufacturer rep if you're buying >$100k annually; volume often unlocks better base pricing than published tiers. Finally, don't chase rebates blindly—if switching 30% of your Botox volume to Jeuveau saves $0.50 per unit but costs you 15% of patients (who prefer Botox), the math fails. Rebate optimization is margin enhancement, not patient acquisition.